NanoDimension is a venture capital firm investing in disruptive technologies in and at the convergence of the life and physical sciences.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
NanoDimension is a leading venture capital firm investing in disruptive technologies in and at the convergence of the life and physical sciences. We focus on early stage opportunities in the US and Europe led by exceptional entrepreneurs. NanoDimension’s investment team takes an active approach to building portfolio companies, leveraging our expertise and network to find and build companies with innovative solutions to critical global problems.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2010 | Crocus Technology | Series C | 0 |
6/2012 | View | Series D | 0 |
7/2014 | Emulate | Series A | 12M |
1/2016 | Pulse Therapeutics | Venture Round | 10M |
7/2013 | Crocus Technology | Series D | 0 |
4/2019 | Inscripta | Series C | 0 |
4/2010 | Selecta Biosciences | Series C | 15M |
1/2016 | Twist Bioscience | Series D | 61M |
1/2015 | Tarveda Therapeutics | Series B | 21M |
2/2017 | Inscripta | Series B | 23M |
1/2012 | Tarveda Therapeutics | Series A | 2.8M |
5/2014 | ARMO BioSciences | Series B | 30M |
6/2015 | Crocus Technology | Series E | 21M |
11/2013 | View | Venture Round | 12.6M |
10/2008 | Crocus Technology | Series B | 15.9M |
7/2018 | Serotiny | Seed Round | 3M |
9/2019 | Amphivena Therapeutics | Series C | 0 |
6/2010 | BIND Therapeutics | Series C | 12.4M |
12/2013 | Tarveda Therapeutics | Series B | 21M |
9/2015 | Selecta Biosciences | Series E | 38M |
10/2014 | Selecta Biosciences | Private Equity Round | 20M |
9/2016 | SQZ Biotech | Series B | 16M |
5/2020 | SQZ Biotech | Series D | 0 |
2/2009 | Selecta Biosciences | Series B | 15.1M |
8/2018 | SQZ Biotech | Series C | 0 |
5/2014 | Twist Bioscience | Series B | 26M |
12/2018 | Inscripta | Series C | 0 |
2/2018 | Inscripta | Series C | 55.5M |
4/2021 | Icosavax | Series B | 0 |
12/2010 | View | Series C | 40M |
2/2017 | Tarveda Therapeutics | Series D | 30M |
12/2019 | Arctos Medical | Seed Round | 0 |
10/2019 | Icosavax | Series A | 0 |
3/2008 | Xtellus | Venture Round | 8.3M |
1/2010 | SBA Materials | Venture Round | 5.2M |
6/2015 | Twist Bioscience | Series C | 37M |
10/2016 | Emulate | Series B | 0 |
2/2016 | ARMO BioSciences | Series C | 50M |
8/2017 | ARMO BioSciences | Series C | 0 |
11/2007 | BIND Therapeutics | Series B | 16M |
7/2020 | Natron Energy | Series D | 0 |
2/2018 | H55 | Venture Round | - |
4/2021 | Icosavax | Series B | 0 |
7/2020 | Natron Energy | Series D | 0 |
5/2020 | SQZ Biotech | Series D | 0 |
12/2019 | Arctos Medical | Seed Round | 0 |
10/2019 | Icosavax | Series A | 0 |
9/2019 | Amphivena Therapeutics | Series C | 0 |
4/2019 | Inscripta | Series C | 0 |
12/2018 | Inscripta | Series C | 0 |
8/2018 | SQZ Biotech | Series C | 0 |
7/2018 | Serotiny | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|